Related Experiment Videos
Pharmacokinetics of benzodiazepines and psychostimulants in children
Insights
Infants metabolize diazepam slowly, with limited biotransformation capacity before 5 months. Methylphenidate pharmacokinetics in children resemble adults, but toxicity risk increases with dosage.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Drug Metabolism
Background:
- Benzodiazepines and psychostimulants are commonly used in pediatric populations.
- Understanding drug pharmacokinetics in infants and children is crucial for safe and effective treatment.
- Limited data exists on the specific pharmacokinetic profiles of these drug classes in young children.
Purpose of the Study:
- To review the pharmacokinetics of benzodiazepines and psychostimulants in infancy and childhood.
- To provide an overview of kinetic principles relevant to pediatric drug utilization.
- To highlight the implications of developmental changes on drug metabolism and elimination.
Main Methods:
- Review of existing pharmacokinetic studies on diazepam (a benzodiazepine) and methylphenidate (a psychostimulant) in pediatric populations.
- Analysis of drug metabolism pathways, including hydroxylation, demethylation, and glucuronide conjugation.
- Examination of half-life, rate of biotransformation, and volume of distribution.
Main Results:
- Newborns and premature infants exhibit slower diazepam metabolism and elimination, with a longer half-life compared to older children and adults.
- Hepatic enzyme capacity for diazepam biotransformation matures by 5 months of age.
- Methylphenidate pharmacokinetics in children are similar to adults, with rapid metabolism to ritalinic acid and a short half-life; however, toxicity potential increases with dosage.
Conclusions:
- Developmental stage significantly impacts benzodiazepine pharmacokinetics, necessitating careful dosing in neonates and infants.
- Methylphenidate's pharmacokinetic profile in children is relatively well-defined, but toxicity monitoring is essential.
- Advancements in microsampling and noninvasive urinary studies will facilitate future pediatric pharmacokinetic research.
Abstract:
The pharmacokinetics of benzodiazepines and psychostimulants are reviewed and an overview of the kinetic principles relevant to the utilization of these drugs in infancy and childhood is provided. Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and decreased rate of biotransformation to its primary metabolites than in older children and adults. The newborn's capacity to carry on metabolic processes involved in the biotransformation of diazepam, including hydroxylation, demethylation, and glucuronide conjugation, is also limited before 5 months of age; after this time hepatic enzymes develop to adult capacity. Kinetic studies of psychostimulants in childhood indicate that methylphenidate is metabolized in the child as it is in the adult. The drug appears to be rapidly metabolized to ritalinic acid and the half-life seems to be relatively short. Volumes of distribution appear to be relatively large, suggesting extensive distribution of the drug to body tissues. Neither diazepam nor methylphenidate is without the potential for toxicity, which increases with dosage. The authors conclude that advancements in the technical capacity for obtaining and analyzing microsamples of blood as well as the use of noninvasive urinary studies will make future research in children possible.